NCT06014086View on ClinicalTrials.gov

Intratumoral PH-762 for Cutaneous Carcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 7, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

April 30, 2026

Conditions
Squamous Cell Carcinoma of the SkinMalignant Melanoma of SkinMerkel Cell Carcinoma of Skin
Interventions
DRUG

PH-762

PH-762 is a potent RNAi molecule targeting PD-1.

Trial Locations (5)

33445

RECRUITING

Integrity Research, Delray Beach

43213

RECRUITING

Centricity Research, Columbus

85234

RECRUITING

Banner MD Anderson Cancer Center, Gilbert

89509

RECRUITING

Skin Cancer and Dermatology Institute, Reno

92108

RECRUITING

Paradigm Clinical Research, San Diego

Sponsors
All Listed Sponsors
collaborator

Prosoft Clinical

OTHER

lead

Phio Pharmaceuticals Inc.

INDUSTRY